Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study
Authors:
- 1 October 2019
- journal article
- research article
- Published by Elsevier in The Ocular Surface
- Vol. 17 (4) , 828-832
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Research to Prevent Blindness
This publication has 18 references indexed in Scilit:
- Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral ConjunctivitisAmerican Journal of Ophthalmology, 2019
- Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral ConjunctivitisAmerican Journal of Ophthalmology, 2018
- Treatment of adenoviral keratoconjunctivitis with a combination of povidone‐iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized studyActa Ophthalmologica, 2017
- Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injectionsCutaneous and Ocular Toxicology, 2017
- Treatment of Epidemic Keratoconjunctivitis with 2% Povidone–Iodine: A Pilot StudyJournal of Ocular Pharmacology and Therapeutics, 2011
- A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitisAdvances in Therapy, 2009
- The characteristics of corneal staining in successful daily and extended disposable contact lens wearersClinical and Experimental Optometry, 1999
- CCLRU Standards for Success of Daily and Extended Wear Contact LensesOptometry and Vision Science, 1993
- Prophylaxis of Endophthalmitis with Topical Povidone-iodineOphthalmology, 1991
- Keratokonjunktivitis epidemica: Therapieergebnisse während einer EpidemieKlinische Monatsblätter für Augenheilkunde, 1990